#United States #AbbVie #North Chicago #Skyrizi #IPRD

Financial Performance Overview

AbbVie Inc. has recently shared its financial outcomes for the full year and the fourth quarter ending December 31, 2025. The comprehensive report highlights various metrics that reflect AbbVie’s performance amid a dynamic pharmaceutical landscape.

Key Financial Highlights

The diluted earnings per share (EPS) for the full year stands at $2.36 based on GAAP, marking a 1.3% decline from the previous year. Adjusted diluted EPS fell slightly by 1.2% to $10.00. However, this figure excludes specific expenses linked to acquired intellectual property research and development (IPRD) and milestone payments, which impacted results unfavorably by approximately $2.76 per share.

AbbVie's net revenues in 2025 reached $61.16 billion, showing a robust increase of 8.6%, both on reported and operational bases. Significantly, revenues from the immunology portfolio surged by 14.0% to $30.41 billion, driven primarily by strong sales of leading products like Skyrizi and Rinvoq.

• - Skyrizi, a key immunology product, generated $17.56 billion, reflecting a solid performance with a 49.9% rise.
• - Rinvoq contributed $8.30 billion, achieving a 39.1% increase.
• - Humira, once a flagship product for AbbVie, faced a decline, resulting in revenue of $4.54 billion, a drop of 49.5% as it lost exclusivity in the U.S. market.

From the neuroscience segment, AbbVie also reported a notable 19.6% revenue increase to $10.77 billion, led by products such as Vraylar, which earned $3.62 billion, and Botox Therapeutic, which brought in $3.77 billion. The oncology portfolio showed mixed results, with total revenues of $6.66 billion, increasing by 1.5%. Here, Imbruvica saw a downturn, while Venclexta maintained a slight growth.

Fourth-Quarter Insights

In Q4 of 2025, AbbVie posted a net revenue of $16.618 billion, reflecting a 10% increase compared to Q4 2024. Immunology net revenues for this quarter reached $8.626 billion, bolstered primarily by sales from Skyrizi and Rinvoq.

Notable declines were observed in aesthetics, with revenues of $1.286 billion, which showcases a decreasing trend driven largely by Botox Cosmetic and Juvederm collections.

The reported gross margin on a GAAP basis was recorded at 72.6% in Q4, with an adjusted gross margin of 83.6%. This financial maneuvering underlines AbbVie’s operational efficiency amid evolving market conditions.

Guidance for 2026

Looking ahead, AbbVie has released its guidance for adjusted diluted EPS for 2026, estimated between $14.37 to $14.57, excluding the effects of potential unfavorable IPRD and milestone expenses. This projection indicates optimism grounded in the company’s strategic growth plan and dedication to fostering innovation in pharmaceuticals.

Proactive Innovations and Strategic Developments

AbbVie has been actively advancing its drug pipeline with plans for several new indications and extensions. Notable submissions to health authorities include Rinvoq's application for treating vitiligo and expanded use of Aquipta for migraine relief.

Additionally, AbbVie has secured FDA approval for Epkinly in combination therapies for follicular lymphoma, further establishing its commitment to enhancing treatment options for patients facing relapsing diseases.

In a major corporate move, AbbVie announced a partnership with RemeGen for RC148, showcasing its continuous efforts toward innovation in oncology therapies. Furthermore, AbbVie outlined a significant investment in U.S. research and development, pledging $100 billion over the next decade to bolster domestic pharmaceutical innovation and manufacturing.

Conclusion

In conclusion, AbbVie has demonstrated strong financial health in 2025 despite market challenges. The strategic focus on innovation and comprehensive patient treatment solutions positions the company well for sustained growth in the upcoming year.